LIR Life Sciences Corp.
BBCMF
$1.42
$0.075.54%
OTC PK
| 10/31/2025 | 07/31/2025 | 10/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | 7.30K | -- | ||
| Gross Profit | -- | -7.30K | -- | ||
| SG&A Expenses | 140.40K | 93.80K | 30.70K | ||
| Depreciation & Amortization | 1.00K | 800.00 | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 141.40K | 101.90K | 30.70K | ||
| Operating Income | -141.40K | -101.90K | -30.70K | ||
| Income Before Tax | -141.20K | -102.00K | -30.70K | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -141.20K | -102.00K | -30.70K | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -141.20K | -102.00K | -30.70K | ||
| EBIT | -141.40K | -101.90K | -30.70K | ||
| EBITDA | -140.40K | -101.10K | -- | ||
| EPS Basic | -0.01 | -0.01 | -0.61 | ||
| Normalized Basic EPS | 0.00 | 0.00 | -0.38 | ||
| EPS Diluted | -0.01 | -0.01 | -0.61 | ||
| Normalized Diluted EPS | 0.00 | 0.00 | -0.38 | ||
| Average Basic Shares Outstanding | 19.39M | 19.00M | 50.00K | ||
| Average Diluted Shares Outstanding | 19.39M | 19.00M | 50.00K | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||